Clover Biopharmaceuticals is harnessing the full potential of its proprietary Trimer-Tag© platform technology to target trimerization-dependent pathways involved in the pathology of a spectrum of debilitating diseases. We leverage our cutting-edge technology and fully integrated manufacturing capabilities to discover, develop and deliver innovative and affordable medical solutions to improve the quality of life for patients around the world.
Trimer-Tag© is a cutting-edge drug discovery and development platform that allows for the production of novel, covalently trimerized fusion proteins to effectively target previously difficult to target pathways.
Many major disease targets are trimerization-dependent such as the tumor necrosis factor (TNF) superfamily (involved in extrinsic apoptosis, immune co-stimulation and inflammation) as well as enveloped RNA virus antigens responsible for entry into host cells. Clover’s technology has paved the way for a robust portfolio of programs including protein-based subunit vaccines and cancer therapeutics to treat the world’s most debilitating diseases and public health threats.